Biotech & Medicine
133 articles RSS
Gilead's Single-Tablet HIV Regimen Matches Complex Multi-Pill Therapies in Two Phase 3 Trials, Lancet Reports
Two Phase 3 ARTISTRY trials show bictegravir/lenacapavir maintains viral suppression while replacing regimens of up to 11 daily pills with one tablet.
Base Editing Corrects a Genetic Disease for the First Time in Living Patients, Putting BEAM-302 on Track for FDA Accelerated Approval
Beam Therapeutics' BEAM-302 has achieved the first-ever in-vivo base editing correction of a disease-causing mutation in human patients, reaching therapeutic AAT levels in a Phase 1/2 trial for alpha-1 antitrypsin deficiency. A pivotal Q1 2026 data readout is now imminent.
PRIMA Retinal Implant Restores Reading Ability in 81 Percent of Blind Patients, NEJM Finds
The PRIMA wireless retinal implant restored reading ability in 81 percent of blind AMD patients in a landmark NEJM trial — the first device to restore true form vision.
Keytruda Becomes First Immunotherapy to Extend Survival in Platinum-Resistant Ovarian Cancer
FDA approves pembrolizumab for a subset of ovarian cancer patients after Phase 3 KEYNOTE-B96 trial shows the first overall survival benefit ever demonstrated by an immunotherapy in this setting.
Blood Test Can Forecast When Alzheimer's Symptoms Will Begin, Study in Nature Medicine Finds
A Washington University team showed a p-tau217 blood test can estimate Alzheimer's symptom onset within 3-4 years, potentially transforming early intervention and clinical trials.
Merck's Once-Daily Cholesterol Pill Matches Injectable Efficacy in Phase 3 Trial, Opening Path to First Oral PCSK9 Inhibitor
Enlicitide decanoate cut LDL cholesterol by 57% in 2,900+ patients in the CORALreef Lipids Phase 3 trial — matching injectable PCSK9 inhibitors in pill form, with no meaningful safety signals over 52 weeks.
UC San Diego Team Builds a CRISPR Gene Drive That Spreads Through Bacteria and Strips Away Antibiotic Resistance
A second-generation Pro-Active Genetics system spreads via bacterial conjugation to disable resistance genes on plasmids, working even inside biofilms.
Scientists Identify the Enzyme That Shatters Chromosomes in One in Four Cancers, Revealing a New Target for Drug Resistance
UC San Diego researchers identify N4BP2 as the molecular trigger behind chromothripsis, the catastrophic chromosome-shattering event that drives treatment resistance in roughly a quarter of human cancers.
FDA Approves First Wearable Electric-Field Device for Pancreatic Cancer, the Disease's First New Treatment in Nearly Three Decades
Novocure's Optune Pax uses tumor treating fields to extend survival by two months in locally advanced pancreatic cancer, earning FDA approval through its most rigorous pathway.
Scientists Pinpoint the Brain Network Behind Parkinson's Disease and Show All Major Therapies Converge on It
An 863-person Nature study identifies the SCAN brain network as the core driver of Parkinson's, with all four major treatments working by reducing its abnormal hyperconnectivity.
The FDA's Plausible Mechanism Pathway: How Baby KJ's Personalized CRISPR Therapy Is Rewriting the Rules of Drug Approval
The FDA's new Plausible Mechanism Pathway enables approval of one-patient gene editing therapies without traditional clinical trials, inspired by the first personalized CRISPR cure for an infant with a fatal metabolic disorder — but ethicists warn of a regulatory Pandora's box.
Moderna-Merck Personalized mRNA Cancer Vaccine Sustains 49% Melanoma Risk Reduction at Five Years
Five-year KEYNOTE-942 trial data show Moderna and Merck's individualized neoantigen mRNA vaccine maintains a 49% reduction in melanoma recurrence or death.